Business Context and Reporting Period
This Form 8-K filing by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) reports on events occurring on February 15, 2019, with the report dated February 22, 2019. The filing details the completion of a rights offering to shareholders.
Key Financial Metrics
- Gross Proceeds: Approximately $34.6 million raised from the sale of approximately 47.8 million units.
- Unit Price: $0.724 per unit.
- Unit Composition: One share of common stock and one immediately exercisable warrant with a strike price of $1.47 per share.
- Major Investment: Entities controlled by Chairman Gregg Williams acquired approximately 41.4 million units for an aggregate investment of approximately $30 million.
- Capital Structure Impact: The company expects to have 124,197,961 shares of common stock and 62,261,657 warrants outstanding as of February 21, 2019.
Material Changes
The primary material change is the successful completion of the rights offering, which expired on February 15, 2019. Unexercised subscription rights have expired. Additionally, the company amended the Warrant Agreement to extend the expiration date of all outstanding warrants listed under the "EYESW" symbol to March 14, 2024.
Outlook, Risks, and Management Commentary
Management confirmed the issuance of a press release on February 21, 2019, announcing the completion of the offering. The filing notes that the final distribution of shares and warrants was expected on or about February 22, 2019. No specific forward-looking guidance regarding revenue or operational milestones is provided in this specific filing text.
Investor Verification Checklist
- Verify the final number of shares and warrants issued as of February 21, 2019.
- Confirm the trading status and CUSIP of the warrants under the "EYESW" symbol on Nasdaq.
- Review the full text of the Amendment No. 1 to the Warrant Agreement (Exhibit 99.2) for specific terms regarding the two-year extension.
- Check subsequent filings for the actual cash balance impact of the $34.6 million gross proceeds.